Trial Profile
Phase II clinical study of nab-PTX/CBDCA (administer 3-weeks on / 1-week off) for patients with clinical stage IIIB/IV or recurrent NSCLC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jul 2018 Status changed from recruiting to discontinued.
- 20 Jan 2015 New trial record